Review
Medicine, General & Internal
Abdullah Tarik Aslan, Yukiko Ezure, Juan Pablo Horcajada, Patrick N. A. Harris, David L. Paterson
Summary: This study evaluated the efficacy of ceftazidime-avibactam (CZA) combination regimens compared to CZA monotherapy against carbapenem-resistant Enterobacterales (CRE) and multidrug-resistant Pseudomonas aeruginosa (MDR-PA) isolates or infections. The results showed reliable in vitro synergy between CZA and aztreonam against metallo-beta-lactamase (MBL)-producing isolates. Some studies demonstrated good in vitro synergy between CZA and other antibiotics against CRE isolates. For MDR-PA isolates, there were fewer in vitro and in vivo studies. In clinical studies, the outcomes were generally similar between monotherapy and combination therapy groups, but there were higher rates of nephrotoxicity and infection relapse in patients receiving CZA combination therapies.
FRONTIERS IN MEDICINE
(2023)
Article
Infectious Diseases
Amelia Bhatnagar, Eric M. Ransom, Maria-Jose Machado, Sandra Boyd, Natashia Reese, Karen Anderson, David Lonsway, Christopher A. Elkins, J. Kamile Rasheed, Jean B. Patel, Maria Karlsson, Allison C. Brown, Joseph D. Lutgring
Summary: This study aimed to determine whether increasing ceftazidime concentrations affect the MICs of aztreonam/avibactam. Testing on 37 Enterobacteriales isolates with intermediate or resistant interpretations to aztreonam and ceftazidime/avibactam showed that ceftazidime did not affect the in vitro activity of aztreonam/avibactam in the combination.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Public, Environmental & Occupational Health
Hai-Hui Zhuang, Ying Chen, Qin Hu, Wen-Ming Long, Xiao-Li Wu, Qin Wang, Tian-Tian Xu, Qiang Qu, Yi-Ping Liu, Yi-Wen Xiao, Jian Qu
Summary: This study retrospectively evaluated the clinical and microbiological efficacy, patient mortality, and other associated factors of ceftazidime/avibactam (CAZ/AVI)-based regimens for carbapenem-resistant Gram-negative bacteria (CR-GNB). The results showed that CAZ/AVI had good clinical and microbiological efficacy in treating CR-GNB infection, but renal dysfunction and the adjusted dose of CAZ/AVI could affect efficacy. Rating: 8 out of 10.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2023)
Article
Infectious Diseases
Annabel Werumeus Buning, Caspar J. Hodiamont, Natalia M. Lechner, Margriet Schokkin, Paul W. G. Elbers, Nicole P. Juffermans, Ron A. A. Mathot, Menno D. de Jong, Reinier M. van Hest
Summary: This study aimed to describe the population pharmacokinetics of ceftazidime in critically ill patients with Pseudomonas aeruginosa infection, and found that patient characteristics and treatment methods can affect drug clearance, suggesting the use of loading doses for patients with proven or suspected P. aeruginosa infection.
Article
Infectious Diseases
Jessica R. Tait, Hajira Bilal, Tae Hwan Kim, Abigail Oh, Anton Y. Peleg, John D. Boyce, Antonio Oliver, Phillip J. Bergen, Roger L. Nation, Cornelia B. Landersdorfer
Summary: The study showed that the combination of ceftazidime and tobramycin has a good bactericidal effect and can suppress resistance in hypermutable Pseudomonas aeruginosa strains. In vitro experiments simulating treatment regimens revealed that high-dose combination therapy is more effective against susceptible strains.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Infectious Diseases
Yixin Kang, Qian Zhou, Junchang Cui
Summary: This study evaluated the efficacy of ceftazidime/avibactam in treating patients with KPC-Kp pulmonary infections, and the recommended dose was found to provide adequate pharmacodynamic exposure.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Review
Pharmacology & Pharmacy
Emily N. Drwiega, Keith A. Rodvold
Summary: The review summarizes studies on drug penetration into pulmonary epithelial lining fluid, focusing on comparisons of plasma and ELF concentrations of antibacterial agents in healthy adult subjects and critically ill patients. The significance of changes in intrapulmonary penetration and the need for further studies relating ELF concentrations to clinical response are highlighted. Studies are warranted to evaluate the relationship between intrapulmonary penetration and clinical and microbiological outcomes in critically ill patients with lower respiratory tract infections.
CLINICAL PHARMACOKINETICS
(2022)
Article
Infectious Diseases
Xiao-Shan Zhang, Yu-Zhen Wang, Da-Wei Shi, Fang-Min Xu, Jun-Hui Yu, Jie Chen, Guan-Yang Lin, Chun-Hong Zhang, Xu-Ben Yu, Cong-Rong Tang
Summary: This article describes two cases of patients receiving renal replacement therapy who were treated with ceftazidime-avibactam. In the case of intermittent hemodialysis (IHD), 2.5 g of CZA was administered after each session of IHD, with an additional dose of 1.25 g given during the interdialytic interval. In the case of continuous venovenous hemodialysis (CVVHD), 2.5 g of CZA was given every 12 hours in 2-hour infusions. Both dosing regimens maintained effective drug concentrations and exerted antimicrobial effects during the treatment.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Engineering, Environmental
Ashmi Mishra, Steven Lelieveld, Ulrich Poeschl, Thomas Berkemeier
Summary: Exposure to ambient air pollution can lead to oxidative stress and damage in the respiratory tract. This study investigates the chemical modification of proteins by reactive species from air pollution and biological sources. Fine particulate matter and nitrogen dioxide synergistically increase the formation of a biomarker of oxidative stress, nitrotyrosine. Ozone affects the antioxidant defense system but does not significantly influence nitrotyrosine concentration.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2023)
Article
Environmental Sciences
Yun-Chung Hsiao, Chih-Wei Liu, Carole Robinette, Noelle Knight, Kun Lu, Meghan E. Rebuli
Summary: This study developed a high resolution LC-MS untargeted method to analyze non-invasively collected nasal epithelial lining fluid (NELF). Baseline profiling of 27 samples detected 2002 unknown molecules, including environmental pollutants and endogenous metabolites. The analytical pipeline has high potential for future respiratory health studies.
JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
(2022)
Article
Engineering, Environmental
Steven Lelieveld, Jake Wilson, Eleni Dovrou, Ashmi Mishra, Pascale S. J. Lakey, Manabu Shiraiwa, Ulrich Poeschl, Thomas Berkemeier
Summary: Air pollutants such as aerosols and ozone can cause the generation of reactive oxygen species in the human respiratory tract, leading to oxidative stress and adverse health effects.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2021)
Article
Microbiology
Keith A. Rodvold, Justin Bader, Jon B. Bruss, Kamal Hamed
Summary: SPR206, a next-generation polymyxin, shows promise for treating multidrug-resistant (MDR) Gram-negative infections. A Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206's safety and pharmacokinetics in healthy volunteers. The study demonstrates the pulmonary penetration of SPR206 and supports its further development for the treatment of serious infections caused by MDR Gram-negative pathogens.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Urology & Nephrology
Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Islam M. Ghazi, Nizar Attallah, Rania El Lababidi, Mohamad Mooty, Muriel Ghosn, Jihad Mallat
Summary: The study aimed to evaluate the microbiologic cure of ceftazidime-avibactam in patients utilizing renal replacement therapies (RRTs). The results showed higher clinical cure rates, lower recurrence rates, and lower all-cause mortality rates in the microbiologic cure group. The drug daily dose and bacterial species were identified as independent factors associated with microbiologic cure. Further recommendations need to be made for patients utilizing RRTs based on these findings.
HEMODIALYSIS INTERNATIONAL
(2023)
Article
Infectious Diseases
Guanhao Zheng, Jiaqi Cai, Liang Zhang, Dayu Chen, Linyu Wang, Yusi Qiu, Han Deng, Hao Bai, Xiaolan Bian, Juan He
Summary: The study evaluated the efficacy and safety of ceftazidime/avibactam and polymyxin B in treating carbapenem-resistant Klebsiella pneumoniae infection. The results showed that ceftazidime/avibactam was more effective than polymyxin B in treating CRKP-infected patients. Additionally, the combination of ceftazidime/avibactam with tigecycline or amikacin showed a lower mortality rate. A treatment period lasting over 7 days was recommended, and caution should be taken regarding the hepatotoxicity of ceftazidime/avibactam and the nephrotoxicity of polymyxin B.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Medicine, General & Internal
Akash Gupta, Janette K. Burgess, Dirk-Jan Slebos, Simon D. Pouwels
Summary: In this study, a cellulose matrix was used as an absorptive probe for bronchial epithelial lining fluid (bELF) sampling. The absorption and elution capacity of the matrix were validated, and the design of the sampling device was optimized. The bELF probe detected higher concentrations of inflammatory proteins compared to bronchial wash samples, indicating its effectiveness for high-precision bELF sampling.
FRONTIERS IN MEDICINE
(2023)
Review
Microbiology
Jianguo Li, Mark Lovern, Todd Riccobene, Timothy J. Carrothers, Paul Newell, Shampa Das, Angela K. Talley, Margaret Tawadrous
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Microbiology
Shampa Das, Adam Johnson, Laura McEntee, Nicola Farrington, Adam Kirby, Jennifer Unsworth, Ana Jimenez-Valverde, Ruwanthi Kolamunnage-Dona, Justine Bousquet, Laethitia Alibaud, Carole Sable, Magdalena Zalacain, Martin Everett, William Hope
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Microbiology
Shampa Das, Richard Fitzgerald, Asad Ullah, Marcin Bula, Andrea M. Collins, Elena Mitsi, Jesus Reine, Helen Hill, Jamie Rylance, Daniela M. Ferreira, Karen Tripp, Andrea Bertasini, Samantha Franzoni, Mameli Massimiliano, Omar Lahlou, Paola Motta, Philip Barth, Patrick Velicitat, Philipp Knechtle, William Hope
Summary: The study revealed that cefepime and enmetazobactam had similar concentration-time profiles in plasma and epithelial lining fluid, with a partitioning of 60.59% and 53.03% between plasma and ELF, respectively. The findings suggest that the cefepime-enmetazobactam regimen may be a promising treatment option for nosocomial pneumonia caused by multidrug-resistant Enterobacteriaceae.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Letter
Infectious Diseases
Gunnar Kahlmeter, Rafael Canton, Christian G. Giske, John Turnidge
CLINICAL MICROBIOLOGY AND INFECTION
(2020)
Article
Allergy
Iason Thomas, Leonard Q. C. Siew, Krzysztof Rutkowski
Summary: The outbreak of the COVID-19 pandemic has led to a rapid transition to non-face-to-face models of care across allergy services. The use of synchronous telemedicine for outpatient consultations in a tertiary adult allergy center resulted in positive outcomes, with most patients having a very good/good overall experience. Further research is needed to establish screening criteria for selecting suitable new patients.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Letter
Microbiology
Shampa Das, Martin Everett, Magdalena Zalacain, William Hope
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Allergy
Rosamund Sara Casimir-Brown, Lucinda Kennard, Oyindamola Stephanie Kayode, Leonard Q. C. Siew, Michael Makris, Olympia Tsilochristou, Evangelia Chytiroglou, Alla Nakonechna, Krzysztof Rutkowski, Rita Mirakian, Annette Wagner
Summary: The study found that hypersensitivity reactions caused by piperacillin/tazobactam are more common in patients with cystic fibrosis. Patients with negative skin test results but having allergies still tolerated reintroduction of the drug, and most patients exhibited selectively sensitized and tolerated other penicillins.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Microbiology
Christopher A. Darlow, Fernando Docobo-Perez, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez-Valverde, Silke Gastine, Ruwanthi Kolamunnage-Dona, Renata M. A. de Costa, Sally Ellis, Francois Franceschi, Joseph F. Standing, Mike Sharland, Michael Neely, Laura Piddock, Shampa Das, William Hope
Summary: Antimicrobial resistance in neonatal sepsis is a global issue, with high mortality rates in low- and middle-income countries. A combination therapy of fosfomycin and amikacin shows enhanced bactericidal activity and synergy against resistant strains. Monte Carlo simulations support the efficacy of this combination regimen for the treatment of neonatal sepsis.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Andrew Cristinacce, James G. Wright, Merran Macpherson, Joseph Iaconis, Shampa Das
Summary: For recently licensed antibiotics such as ceftaroline fosamil, probability of target attainment (PTA) curves have been used to support dose recommendations, while limited information is available on PTA for older antibiotics. A retrospective analysis was conducted to construct PTA curves for 4 antibiotics against Staphylococcus aureus in patients with complicated skin and soft tissue infections (cSSTIs). Ceftaroline achieved PTAs >99.9% at MIC90, while comparators failed to achieve PTAs >90% even with increased doses.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2021)
Review
Pediatrics
Christopher A. Darlow, Renata M. A. da Costa, Sally Ellis, Francois Franceschi, Mike Sharland, Laura Piddock, Shampa Das, William Hope
Summary: Neonatal sepsis is a major cause of up to 680,000 deaths annually worldwide, with many bacteria developing resistance to antibiotics. Research has identified five antibiotics that meet the criteria for use in neonatal sepsis, but there are still some knowledge gaps that need to be addressed through further studies.
Article
Allergy
Michael S. Blaiss, Ruta Gronskyte Juhl, Leonard Q. C. Siew, Eva Hammerby, Philippe Devillier
Summary: This study determined the minimal important differences (MIDs) between treatment groups in patients with seasonal allergies using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The MIDs were specific to the trial populations and conditions, emphasizing the need for a range of MIDs to reflect the unique nature of seasonal allergic disease.
Article
Infectious Diseases
Christopher A. Darlow, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez-Valverde, Ruwanthi Kolamunnage-Dona, Renata M. A. Da Costa, Sally Ellis, Francois Franceschi, Mike Sharland, Michael Neely, Laura J. Piddock, Shampa Das, William Hope
Summary: This study assessed the efficacy of flomoxef and fosfomycin as a potential alternative treatment for neonatal sepsis in low- and middle-income countries. The combination therapy showed synergy in terms of bacterial killing and prevention of fosfomycin resistance. The findings suggest that flomoxef/fosfomycin could be an effective regimen for neonatal sepsis in settings with antimicrobial resistance.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Microbiology
Nicola Farrington, Laura McEntee, Adam Johnson, Jennifer Unsworth, Christopher Darlow, Ana Jimenez-Valverde, Christoph Hornik, Rachel Greenberg, Julie Schwartz, Shampa Das, William Hope
Summary: Neonatal sepsis is a burden on healthcare systems worldwide, and the increasing prevalence of antimicrobial drug resistance compromises the use of recommended first-line agents. However, the development of new antimicrobial agents for neonatal bacterial meningoencephalitis is still uncertain due to the challenges of studying this disease in clinical settings, particularly in premature infants. In this study, a new platform and approach were developed to accelerate the development of antimicrobial agents for neonatal bacterial meningoencephalitis, using Pseudomonas aeruginosa as the challenge organism. The pharmacodynamics of meropenem and tobramycin were defined in these models, and the results showed significant differences in their antibacterial activities. The developed experimental models can be used to estimate the pharmacodynamics and potential efficacy of currently licensed agents and those in development for neonatal bacterial meningoencephalitis.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Editorial Material
Infectious Diseases
Soren Gatermann, Shampa Das, Luc Dubreuil, Christian G. Giske, Gunnar Kahlmeter, Gerard Lina, Christoffer Lindemann, Alasdair MacGowan, Joseph Meletiadis, Gian Maria Rossolini, John Turnidge, Rafael Canton
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Meeting Abstract
Allergy
Kok Loong Ue, Hannah Hunter, Victoria Cornelius, Ching Ching Yung, Iason Thomas, Olympia Tsilochristou, Leonard QuokChean Siew, Stephen Till
CLINICAL AND EXPERIMENTAL ALLERGY
(2021)